$REGN SEC Filings

Received 17,000 shares by exercise or conversion ($6.49M) · Gave up 12,853 shares to cover exercise price or tax ($9.7M) · Sold 4,147 shares ($3.2M)

On October 1, 2026, Regeneron Pharmaceuticals, Inc., a New York corporation (“Regeneron” or the “Company”), Sanofi Biotechnology SAS, a société par actions simplifée organized under the laws of France (“Sanofi Biotechnology”), and Sanofi...

Plan: Second Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan

Sold 1,215 shares ($1.03M) · Sold 1,131 shares ($970K)

Received 400 shares by exercise or conversion ($288K) · Sold 400 shares ($340K)

Received 12,282 shares by exercise or conversion ($4.69M) · Gave up 9,019 shares to cover exercise price or tax ($7.49M)

Received 6,283 shares by exercise or conversion ($2.4M) · Gave up 4,599 shares to cover exercise price or tax ($3.74M)

Received 400 shares by exercise or conversion ($288K) · Sold 400 shares ($320K)

Received 800 shares by exercise or conversion ($301K) · Sold 800 shares ($640K)

Sold 200 shares ($130K)